A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 135-141

  Bakish, David ^a,b,c   Hooper, Cynthia L ^b,c   Filteau, Marie Josée ^d   Charbonneau, Yoland ^a,e   Fraser, George ^a,b   West, Dixy Lee ^a,b   Thibaudeau, Christine ^b   Raine, Dayle ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c Clinical Epidemiology Program   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

fluvoxamine; imipramine; panic disorder; SSRI; tricyclic antidepressants

Indexed keywords

FLUVOXAMINE; IMIPRAMINE;

ADULT; AGITATION; AGORAPHOBIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PANIC; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TREMOR; VERTIGO; XEROSTOMIA;

ADULT; AGORAPHOBIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; IMIPRAMINE; MALE; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 0029889274     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. American Psychiatric Association. DSM-III-R: The Diagnostic and Statistical Manual of Mental Disorders, 3d ed, revised. Washington, DC: The Association, 1987.
2. Boyer, WF, and Feighner, JP. The efficacy of selective serotonin re-uptake inhibitors in depression. In: Feighner, JP, and Boyer, WF, eds. Selective Serotonin Re-uptake Inhibitors. Chichester: John Wiley & Sons, 1991a. pp. 89-108.
3. Boyer, WF, and Feighner, JP. Side effects of the selective serotonin re-uptake inhibitors. In: Feighner, JP, and Boyer, WF, eds. Selective Serotonin Re-uptake Inhibitors. Chichester: John Wiley & Sons, 1991b. pp. 133-152.
4. Boyer, WF; McFadden, GA; and Feighner, JP. The efficacy of selective serotonin re-uptake inhibitors in anxiety and obsessive compulsive disorder. In: Feighner, JP, and Boyer, WF, eds. Selective Serotonin Re-uptake Inhibitors. Chichester: John Wiley & Sons, 1991. pp 109-117.
5. Bradwejn, J. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: Clinical issues and future directions. Can. J. Psychiatry 38(9, Suppl. 4):S109-S113, 1993.
6. Coryell, W; Noyes, R; and House, JD. Mortality among outpatients with anxiety disorders. Am. J. Psychiatry 143(4):508-510, 1986.
7. de Jonghe, F, and Swinkels, JA. The safety of antidepressants. Drugs 43(2, Suppl.):40-47, 1992.
8. den Boer, JA, and Westenberg, HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder. A double-blind comparative study with fluvoxamine and maprotiline. Int. Clin. Psychopharmacol. 3:59-74, 1988.
9. den Boer, JA; Westenberg, HGM; Kamerbeek, WDJ; Verhoeven, WMA; and Kahn, RS. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int. Clin. Psychopharmacol. 2:21-32, 1987.
10. Derogatis, LR; Lipman, RS; Rickels, K; Uhlenhuth, EH; and Covi, L. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav. Sci. 19:1-15, 1974.
11. Fava, M. Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. Am. J. Psychiatry 150:1158-1163, 1993.
12. Fava, M, and Rosenbaum, JF. Psychopharmacology of pathologic aggression. Harv. Rev. Psychiatry 1:244-246, 1993.
13. Goodman, WK; Price, LH; Delgado, PL; Palumbo, J; Krystal, JH; Nagy, LM; Rasmussen, SA; Heninger, GR; and Charney, DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 47:577-585, 1990.
14. Gorman, JM; Liebowitz, MR; Fyer, AJ; Goetz, D; Campeas, RB; Fyer, MR; Davies, SO; and Klein, DF. An open trial of fluoxetine in the treatment of panic attacks. J. Clin. Psychopharmacol. 7:329-332, 1987.
15. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
16. Hoehn-Saric, R; McLeod, DR; and Hipsley, PA. Effect of fluvoxamine on panic disorder. J. Clin. Psychopharmacol. 13(5):321-326, 1993.
17. Hoffman, L, and Halmi, K. Psychopharmacology in the treatment of anorexia nervosa and bulimia nervosa. Psychiatr. Clin. North Am. 16(4):767-778, 1993.
18. Kasper, S; Fuger, J; and Moller, H-J. Comparative efficacy of antidepressants. Drugs 43(2, Suppl.):11-23, 1992.
19. Lepine, JP; Chignon, JM; and Teherani, M. Suicide attempts in patients with panic disorder. Arch. Gen. Psychiatry 50:144-149, 1993.
20. Marks, IM, and Mathews, AM. Brief standard self-rating for phobic patients. Behav. Res. Ther. 17:263-267, 1978.
21. McDougle, CJ; Goodman, WK; Leckman, JF; and Price, LH. The psychopharmacology of obsessive compulsive disorder: Implications for treatment and pathogenesis. Psychiatr. Clin. North Am. 16(4):749-766, 1993.
22. Montgomery, SA. Suicide and antidepressants. Drugs 43(2, Suppl.):24-31, 1992.
23. Montgomery, SA, and Åsberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-389, 1979.
24. Montgomery, SA; Henry, J; McDonald, G; Dinan, T; Lader, M; Hindmarch, I; Clare, A; and Nutt, D. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9:47-53, 1994.
25. Montgomery, SA, and Manceaux, A. Fluvoxamine in the treatment of obsessive compulsive disorder. Int. Clin. Psychopharmacol. 7(1):5-9, 1992.
26. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
27. Regier, DA; Boyd, JH; Burke, JD; Rae, DS; Myers, JK; Kramer, M; Robins, LN; George, LK; Karno, M; and Locke, BZ. One-month prevalence of mental disorders in the United States: Based on five Epidemiologic Catchment Area sites. Arch. Gen. Psychiatry 45:977-986, 1988.
28. Roy-Byrne, P; Wingerson, D; Cowley, D; and Dager, S. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr. Clin. North Am. 16(4):719-735, 1993.
29. Shear, MK, and Maser, JD. Standardized assessment for panic disorder research. A conference report. Arch. Gen. Psychiatry 51:346-354, 1994.
30. Sheehan, DV. The Anxiety Disease. New York: Bantam Books, 1986.
31. Snaith, RP; Baugh, SJ; Clayden, AD; Hussain, A; and Sipple, MA. The Clinical Anxiety Scale: An instrument derived from the Hamilton Anxiety Scale. Br. J. Psychiatry 141:518-523, 1982.
32. Weissman, MM; Klerman, GL; Markowitz, JS; and Ouelette, R. Suicidal ideation and suicide attempts in panic disorder and attacks. N. Engl. J. Med. 321:1209-1241, 1989.
33. Wood, A. Pharmacotherapy of bulimia nervosa. Experience with fluoxetine. Int. Clin. Psychopharmacol. 8:295-299, 1993.